rights issue

Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option

GOTHENBURG, Sweden, June 14, 2021 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the “Company”) fully guaranteed new share issue with preferential rights for the Company’s existing shareholders (the “Rights Issue”), which ended on June 10, 2021, was oversubscribed. Due to the strong demand from strategic investors, a directed issue with deviation from the shareholders’ preferential rights of approximately SEK 100 million (the “Over-Allotment Option”) was exercised. Through the Rights Issue and the Over-Allotment Option, Isofol will receive proceeds amounting to approximately SEK 500 million before transaction costs.

Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option Read More »

Consortium of investors acquires subscription rights from Isofol´s founder Professor Bengt Gustavsson

GOTHENBURG, Sweden, May 29, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the “Company”), has been informed by Professor Bengt Gustavsson – founder and largest owner of Isofol – that Professor Gustavsson has initiated that all the subscription rights held by Biofol AB (an affiliated company to Professor Gustavsson), obtained in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million, has been purchased by a consortium of investors.

Consortium of investors acquires subscription rights from Isofol´s founder Professor Bengt Gustavsson Read More »

Scroll to Top